ArticleFrontiers in oncology2026
CT-based habitat imaging integrated with radiomics and clinicopathology for noninvasive prediction of microvascular invasion in hepatocellular carcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dynamic Vascular Spatiotemporal Heterogeneity on Multiphase CT for Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop and validate a CT-based habitat imaging model incorporating intratumoral microenvironment heterogeneity analysis for noninvasive preoperative prediction of microvascular invasion (MVI) in hepatocellular carcinoma (HCC), addressing limitations of conventional radiomics in characterizing intra-tumor heterogeneity. Methods: This retrospective study included 216 patients with pathologically confirmed HCC undergoing resection. Preoperative portal venous phase contrast-enhanced CT and corresponding postoperative histopathologic MVI status were collected. Habitat (functional heterogeneous subregion) and conventional radiomic features were extracted. A habitat risk score and radiomic score were calculated. Clinical-pathologic factors (Edmondson grade, p53/CD10 expression, tumor diameter) identified via univariate/multivariate analyzes were integrated into a predictive model visualized as a nomogram. Performance was assessed by AUC, calibration curves, and decision curve analysis (DCA). DeLong's test compared ROC curves. Results: In the training set, the combined model achieved an AUC of 0.862 (95% CI: 0.797-0.926); in the validation set, AUC was 0.814 (95% CI: 0.710-0.918), both significantly outperforming individual models (all P < 0.05). Calibration curves showed good agreement (Hosmer-Lemeshow P = 0.60). DCA indicated net benefit at thresholds of 15%-65%. DeLong's test confirmed the combined model had higher AUC than the clinical model (Z = -3.21, P < .05) and radiomics-only model (Z = -2.05, P < .05). Conclusion: The CT-based habitat imaging model quantified intratumoral heterogeneity and, combined with clinicopathologic data, provided a reliable noninvasive tool for preoperative MVI risk stratification in HCC, with strong clinical potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.